A K63-Ubiquitination Dependent Necroptosis Signaling Network in the Heart
心脏中 K63 泛素化依赖性坏死性凋亡信号网络
基本信息
- 批准号:10090946
- 负责人:
- 金额:$ 38.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-08 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAcuteAddressAdultApoptosisAttenuatedBiologicalCardiacCardiac MyocytesCaspaseCell Death Signaling ProcessCell membraneCessation of lifeComplexDataDilated CardiomyopathyDiseaseEnzymesGene TransferGeneticGoalsHeartHeart InjuriesHeart failureInvestigationLinkMAP3K7 geneMediatingMitochondriaModelingMolecularMusMyocardialMyocardial IschemiaNecrosisOrganellesPathologicPathway interactionsPhosphorylationPhysiologyPilot ProjectsPlayPolyubiquitinationProcessRIPK1 geneRIPK3 geneRegulationReperfusion InjuryRoleSignal TransductionSwellingTNF receptor-associated factor 2TNFRSF1A geneTRAF2 geneTestingTherapeuticUbiquitinationcardioprotectionexperimental studygain of functionin vivoinsightischemic injurymyocardial injurynoveloverexpressionpreventreceptortherapeutic targetubiquitin ligaseubiquitin-protein ligasevector
项目摘要
Project Summary/Abstract
Loss of cardiomyocytes by apoptosis and/or necrosis is a hallmark of cardiac ischemic injury, pathological
remodeling, and end-stage heart failure. Although necrosis was traditionally regarded as a passive and
unregulated process, emerging evidence has shifted this paradigm and identified several forms of “programmed
necrosis”, including death receptor-mediated necrosis (termed “necroptosis”), mitochondria-mediated necrosis,
and other regulated necrotic processes. Despite recent progress, how necroptosis is regulated in the heart
remain largely unknown and preventing necroptotic cardiomyocyte death is still an important challenge. Our pilot
studies identified a new K63-linked polyubiquitination (K63-Ub) dependent necroptosis signaling network that
critically regulates cardiac ischemic injury and pathological remodeling. Intriguingly, the K63-deubiquitinase
CYLD (cylindromatosis) was markedly up-regulated, whereas the E3 ubiquitin ligase TRAF2 (TNF receptor
associated factor-2) was down-regulated, in the heart after ischemia-reperfusion injury. Our preliminary results
further identified CYLD and TRAF2 as an activator and a suppressor of myocardial necroptosis, respectively.
Importantly, cardiomyocyte-specific ablation of CYLD attenuated ischemic injury and adverse remodeling by
inhibiting necroptosis. Acute deletion of TRAF2 in the adult heart caused dilated cardiomyopathy by promoting
necroptosis, whereas TRAF2 gene transfer elicited cardioprotection. Mechanistically, we propose a new K63-
Ub dependent necroptotic regulatory mechanism whereby CYLD deubiquitinates TRAF2 and TAK1, disrupts
TAK1-RIP1 interaction, and promotes the necroptotic complex. As an opposing mechanism, TRAF2 acts as an
E3 ligase for TAK1 to inhibit necroptosis signaling. Thus, the reversible K63-Ub (mainly non-proteolytic)
constitutes a new paradigm of necroptosis signaling with important biological implications. We hypothesize
that the deubiquitinase CYLD, in conjunction with the E3 ligase TRAF2, critically regulate myocardial necroptosis,
ischemic injury, and remodeling, thus representing promising therapeutic targets. Aim 1 will investigate the
opposing roles of K63-Ub modifying enzymes CYLD and TRAF2 in regulating myocardial necroptosis and
ischemic injury in vivo. Aim 2 will define a CYLD/TRAF2 mediated, K63-Ub dependent necroptosis signaling
network in cardiomyocytes. Using genetic and molecular strategies, we will investigate the opposing roles of
CYLD and TRAF2 in regulating myocardial necroptosis under basal conditions and in the setting of ischemic
injury. The proposed studies will provide new insights into the molecular regulation and functional significance
of necroptosis in the heart, which has important translational implications, especially given our preliminary results
revealing CYLD/TRAF2 as key necroptotic regulators and promising targets for ischemic heart disease.
项目总结/摘要
通过凋亡和/或坏死导致的心肌细胞损失是心脏缺血性损伤、病理性损伤和/或心肌损伤的标志。
重塑和终末期心力衰竭虽然坏死传统上被认为是一种被动的,
然而,新出现的证据已经改变了这一范式,并确定了几种形式的“程序化”。
坏死”,包括死亡受体介导的坏死(称为“坏死性凋亡”),凋亡介导的坏死,
和其他受调节的坏死过程。尽管最近的进展,如何坏死性凋亡是调节在心脏
仍然在很大程度上是未知的,预防坏死性心肌细胞死亡仍然是一个重要的挑战。我们的飞行员
研究发现了一种新的K63连接的多聚泛素化(K63-Ub)依赖性坏死性凋亡信号网络,
关键调节心脏缺血性损伤和病理性重塑。有趣的是,K63-去遍在蛋白酶
CYLD(圆柱瘤病)显著上调,而E3泛素连接酶TRAF 2(TNF受体)
相关因子-2)在缺血再灌注损伤后的心脏中下调。我们的初步结果
进一步鉴定CYLD和TRAF 2分别作为心肌坏死性凋亡的激活剂和抑制剂。
重要的是,心肌细胞特异性消融CYLD通过降低心肌细胞的存活率来减轻缺血性损伤和不良重塑。
抑制坏死性凋亡。成人心脏中TRAF 2的急性缺失通过促进
坏死性凋亡,而TRAF 2基因转移引起心脏保护。从机械学上讲,我们提出了一种新的K63-
Ub依赖性坏死性凋亡调节机制,CYLD使TRAF 2和TAK 1去泛素化,
TAK 1-RIP 1相互作用,并促进坏死性凋亡复合物。作为一种相反的机制,TRAF 2作为一种
用于TAK 1的E3连接酶以抑制坏死性凋亡信号传导。因此,可逆的K63-Ub(主要是非蛋白水解的)
构成了具有重要生物学意义的坏死性凋亡信号传导的新范例。我们假设
去泛素化酶CYLD与E3连接酶TRAF 2一起,关键性地调节心肌坏死性凋亡,
缺血性损伤和重塑,因此代表了有希望的治疗靶点。目标1将调查
K63-Ub修饰酶CYLD和TRAF 2在调节心肌坏死性凋亡中的相反作用,
体内缺血性损伤。目的2将定义CYLD/TRAF 2介导的K63-Ub依赖性坏死性凋亡信号转导
心肌细胞中的网络。使用遗传和分子策略,我们将调查的对立作用,
CYLD和TRAF 2在基础条件下和缺血性心肌坏死中的调节作用
损伤这些研究将为深入了解其分子调控和功能意义提供新的思路
心脏坏死性凋亡,这具有重要的翻译意义,特别是考虑到我们的初步结果,
揭示了CYLD/TRAF 2作为关键的坏死性凋亡调节因子和缺血性心脏病的有希望的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Qinghang Liu其他文献
Qinghang Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Qinghang Liu', 18)}}的其他基金
The Deubiquitinase CYLD Controls Multiple Cell Death Pathways in the Heart
去泛素酶 CYLD 控制心脏中的多种细胞死亡途径
- 批准号:
10545046 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
The Deubiquitinase CYLD Controls Multiple Cell Death Pathways in the Heart
去泛素酶 CYLD 控制心脏中的多种细胞死亡途径
- 批准号:
10332100 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
A K63-Ubiquitination Dependent Necroptosis Signaling Network in the Heart
心脏中 K63 泛素化依赖性坏死性凋亡信号网络
- 批准号:
10543111 - 财政年份:2021
- 资助金额:
$ 38.88万 - 项目类别:
A K63-Ubiquitination Dependent Necroptosis Signaling Network in the Heart
心脏中 K63 泛素化依赖性坏死性凋亡信号网络
- 批准号:
10327275 - 财政年份:2021
- 资助金额:
$ 38.88万 - 项目类别:
A Critical TAK1 Signaling Network in Myocardial Survival and Remodeling
心肌存活和重塑中关键的 TAK1 信号网络
- 批准号:
8417375 - 财政年份:2013
- 资助金额:
$ 38.88万 - 项目类别:
A Critical TAK1 Signaling Network in Myocardial Survival and Remodeling
心肌存活和重塑中关键的 TAK1 信号网络
- 批准号:
8606243 - 财政年份:2013
- 资助金额:
$ 38.88万 - 项目类别:
A Critical TAK1 Signaling Network in Myocardial Survival and Remodeling
心肌存活和重塑中关键的 TAK1 信号网络
- 批准号:
9187491 - 财政年份:2013
- 资助金额:
$ 38.88万 - 项目类别:
A Critical TAK1 Signaling Network in Myocardial Survival and Remodeling
心肌存活和重塑中关键的 TAK1 信号网络
- 批准号:
8770054 - 财政年份:2013
- 资助金额:
$ 38.88万 - 项目类别:
Role of TAK1 Signaling Network in Cardiac Hypertrophy
TAK1 信号网络在心脏肥大中的作用
- 批准号:
8235043 - 财政年份:2011
- 资助金额:
$ 38.88万 - 项目类别:
Role of TAK1 Signaling Network in Cardiac Hypertrophy
TAK1 信号网络在心脏肥大中的作用
- 批准号:
8231615 - 财政年份:2011
- 资助金额:
$ 38.88万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Operating Grants